Smith & Nephew plc (SNN)

Market Cap	10.39B
Revenue (ttm)	5.55B
Net Income (ttm)	263.00M
Shares Out	435.97M
EPS (ttm)	0.60
PE Ratio	40.02
Forward PE	12.08
Dividend	$0.75 (3.15%)
Ex-Dividend Date	Apr 1, 2024

Volume	749,283
Open	23.94
Previous Close	24.01
Day's Range	23.80 - 24.02
52-Week Range	21.53 - 33.09
Beta	0.51
Analysts	Buy
Price Target	33.00 (+38.42%)
Earnings Date	Feb 27, 2024

About SNN

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 16, 1999
• Employees: 19,081
• Stock Exchange: NYSE
• Ticker Symbol: SNN

Financial Performance

In 2023, Smith & Nephew's revenue was $5.55 billion, an increase of 6.40% compared to the previous year's $5.22 billion. Earnings were $263.00 million, an increase of 17.94%.

Analyst Forecast

According to one analyst, the rating for SNN stock is "Buy" and the 12-month stock price forecast is $33.0.

Price Target

$33.0

(38.42% upside)

Analyst Consensus: Buy